Compare Bristol-Myers Squibb Co (BMY) vs e l f Beauty Inc (ELF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs e l f Beauty Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while e l f Beauty Inc trades at $72.53 (market cap $4.26B). The key difference: Bristol-Myers Squibb Co is far larger — about 27.3× e l f Beauty Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| BMY | ELF | |
|---|---|---|
Market Cap | $116.30B | $4.26B |
Sector | Health | Technology |
52-Week High | $62.37 | $146.67 |
52-Week Low | $42.60 | $49.57 |
Enterprise Value | $152.24B | $4.89B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ELF Beauty trades at $75.10, down 2.15% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.31 billion in 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights brand expansion and a 32% stock jump in June 2026, though growth is transitioning as the core brand softens.
The outlook is mixed: analyst consensus is evenly split between Buy and Hold, with a $74.42 price target near the current price. Upside potential exists from skincare and international expansion, but risks include cost pressures, tariff exposure, and the need to sustain double-digit sales growth amid competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →
